# Cannabidiol (CBD) Does Not Reduce Cocaine Reward in Schizophrenia Model > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-schizophrenia-substance-use-cocaine-reward-study/ > **Published:** 2026-03-26T06:07:37-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:38:19-04:00 > **Clinical Summary:** This study shows CBD schizophrenia substance use effects do not reduce cocaine reward or self-administration in a mouse model of genetic susceptibility. --- CED Clinical Relevance  #67Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic CbdSchizophreniaSubstance UseCocainePreclinical Journal Progress in neuro-psychopharmacology & biological psychiatry Study Type Clinical Study Population Human participants Why This Matters This preclinical study addresses a critical clinical question: whether CBD could simultaneously treat both schizophrenia symptoms and [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/), given the high comorbidity rates. Understanding CBD’s efficacy in genetic models of schizophrenia vulnerability provides essential groundwork for future human trials. Clinical Summary Researchers used heterozygous neuregulin 1 mice, a validated genetic model of schizophrenia susceptibility, to test whether CBD could reduce cocaine reward and self-administration behaviors. The study found that CBD did not reduce cocaine-induced conditioned place preference or self-administration in these genetically vulnerable mice, despite previous preclinical studies showing CBD’s potential for treating both schizophrenia and [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) separately in healthy animal models. This negative finding in a disease-relevant model suggests CBD’s efficacy may be context-dependent and influenced by underlying genetic vulnerability. Dr. Caplan’s Take “This study tempers enthusiasm about CBD as a dual-purpose treatment for patients with both schizophrenia and substance use disorders. While disappointing, these negative preclinical findings are important guardrails before we pursue costly human trials in this vulnerable population.” Clinical Perspective 🧠 Clinicians should remain cautious about recommending CBD specifically for substance use treatment in patients with schizophrenia or genetic risk factors. This preclinical work suggests that CBD’s therapeutic effects may not translate uniformly across different genetic backgrounds or disease states, highlighting the need for targeted [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) in specific patient populations rather than broad extrapolation from healthy subject data. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabidiol%20%28CBD%29%20does%20not%20reduce%20cocaine%20reward%20or%20self-administration%20in%20a%20mou...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41881417/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41881417/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabidiol%20%28CBD%29%20does%20not%20reduce%20cocaine%20reward%20or%20self-administration%20in%20a%20mou...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41881417/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41881417/](https://pubmed.ncbi.nlm.nih.gov/41881417/) Table of Contents - [FAQ](#FAQ)[Can CBD effectively treat cocaine addiction in patients with schizophrenia?](#Can_CBD_effectively_treat_cocaine_addiction_in_patients_with_schizophrenia) - [Is CBD safe to use in patients with schizophrenia who also have substance use disorders?](#Is_CBD_safe_to_use_in_patients_with_schizophrenia_who_also_have_substance_use_disorders) - [Why might CBD work differently in people with schizophrenia compared to healthy individuals?](#Why_might_CBD_work_differently_in_people_with_schizophrenia_compared_to_healthy_individuals) - [Should we abandon CBD research for treating addiction in psychiatric populations?](#Should_we_abandon_CBD_research_for_treating_addiction_in_psychiatric_populations) - [What are the clinical implications of this negative finding?](#What_are_the_clinical_implications_of_this_negative_finding) - [Related](#Related) ## FAQ #### Can CBD effectively treat cocaine addiction in patients with schizophrenia? Based on this preclinical study using a mouse model of schizophrenia genetic susceptibility, CBD did not reduce cocaine reward or self-administration behaviors. This suggests that CBD may not be effective for treating cocaine use disorder in individuals with schizophrenia, though human studies are needed to confirm these findings. #### Is CBD safe to use in patients with schizophrenia who also have substance use disorders? While this study focused on efficacy rather than safety, it provides important evidence that CBD’s effects may differ in populations with genetic susceptibility to schizophrenia compared to healthy individuals. Clinicians should exercise caution and await further research before recommending CBD for dual diagnosis patients. #### Why might CBD work differently in people with schizophrenia compared to healthy individuals? This study used mice with neuregulin 1 gene mutations that model genetic risk for schizophrenia, and these animals showed altered responses to cannabinoids. This suggests that the neurobiological changes associated with schizophrenia susceptibility may affect how CBD interacts with reward and addiction pathways. #### Should we abandon CBD research for treating addiction in psychiatric populations? No, this single preclinical study focused specifically on cocaine addiction in a schizophrenia model. Further research is needed to evaluate CBD’s potential for other substances of abuse and in different psychiatric conditions before drawing broader conclusions about its therapeutic utility. #### What are the clinical implications of this negative finding? This study highlights the importance of testing treatments in disease-relevant models rather than assuming efficacy will translate from healthy populations. Clinicians should be cautious about extrapolating CBD research from healthy subjects to patients with psychiatric comorbidities and substance use disorders. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Cannabidiol (CBD) does not reduce cocaine reward or self-administration in a mouse model of schizophrenia genetic susceptibility.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41881417/”, “about”: “progress neuro psychopharmacology biological psychiatry clinical”, “isPartOf”: “Progress in neuro-psychopharmacology & biological psychiatry”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Is Cannabis Effective for Treating Mental Health Disorders? – Labroots](https://cedclinic.com/cannabis-mental-health-treatment-challenges/) Explore current research on cannabis and its effects on various [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), including schizophrenia and substance use. [Read More](https://cedclinic.com/cannabis-mental-health-treatment-challenges/) [Researchers Identify Genetic Pathways Linking Cannabis Use Disorder and Psychosis Risk](https://cedclinic.com/researchers-identify-genetic-pathways-linking-cannabis-use-disorder-and-psychosis-risk/) This article discusses genetic links between [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and psychosis, relevant to understanding CBD effects in schizophrenia. [Explore Study](https://cedclinic.com/researchers-identify-genetic-pathways-linking-cannabis-use-disorder-and-psychosis-risk/) New Studies Illuminate Health Effects of Cannabis Use – NUG Magazine A summary of recent studies on [cannabis health effects](https://cedclinic.com/cannabis-beverages-alcohol-substitution-research/), including implications for psychiatric and substance use disorders. Learn More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).